Holen Sie sich die Stockscreener-App
0.965
0.86%
0.0033
Schlusskurs vom Vortag:
$0.9617
Offen:
$0.96
24-Stunden-Volumen:
65,494
Relative Volume:
0.18
Marktkapitalisierung:
$51.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-131.52M
KGV:
-0.4447
EPS:
-2.17
Netto-Cashflow:
$-107.56M
1W Leistung:
-5.83%
1M Leistung:
-45.51%
6M Leistung:
-76.28%
1J Leistung:
-69.97%
1-Tages-Spanne:
$0.94
$0.9736
1-Wochen-Bereich:
$0.931
$1.075
52-Wochen-Spanne:
$0.931
$6.80
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Firmenname
Prelude Therapeutics Inc
Sektor
Branche
Telefon
(302) 467-1280
Adresse
175 INNOVATION BOULEVARD, WILMINGTON
Vergleichen Sie PRLD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| PRLD | 0.97 | 51.80M | 0 | -131.52M | -107.56M | -2.17 |
| VRTX | 449.81 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.23 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.46 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.98 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.53 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-21 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | Eingeleitet | Jefferies | Buy |
| 2022-03-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-02-28 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-10-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-04-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2020-11-20 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-10-20 | Eingeleitet | BofA Securities | Buy |
| 2020-10-20 | Eingeleitet | Goldman | Neutral |
| 2020-10-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Prelude Therapeutics Inc Aktie (PRLD) Neueste Nachrichten
Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD) - MSN
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Update - MarketBeat
Prelude Therapeutics' SWOT analysis: biotech stock faces pivotal data readouts - Investing.com
PRLD Stock Touches 52-Week Low at $1.1 Amid Market Challenges - Investing.com
Prelude Therapeutics (NASDAQ:PRLD) Receives Buy Rating from HC Wainwright - Defense World
Prelude Therapeutics Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Prelude Therapeutics Reports Q3 2024 Results and Clinical Progress - MSN
Prelude Therapeutics (NASDAQ:PRLD) Given "Buy" Rating at HC Wainwright - MarketBeat
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
PRLD stock touches 52-week low at $1.32 amid market challenges - Investing.com Australia
Prelude Therapeutics’ (PRLD) Buy Rating Reiterated at HC Wainwright - Defense World
PRLD stock touches 52-week low at $1.32 amid market challenges By Investing.com - Investing.com South Africa
Prelude Therapeutics' SWOT analysis: biotech stock faces pivotal data readouts By Investing.com - Investing.com South Africa
Prelude Therapeutics (NASDAQ:PRLD) Receives "Buy" Rating from HC Wainwright - MarketBeat
Prelude Therapeutics price target lowered to $1 from $3 at Barclays - Yahoo Finance
Prelude Therapeutics Shares Promising Phase 1 Trial Data for PRT3789 at International Symposium - MyChesCo
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium - Yahoo Finance
PRLD stock touches 52-week low at $1.65 amid market challenges - Investing.com India
PRLD stock touches 52-week low at $1.65 amid market challenges By Investing.com - Investing.com South Africa
Deal Watch: Lilly Turns To Oblique For Antibody Discovery - Scrip
Oncopia Therapeutics and University of Michigan divulge new SMARCA2 and SMARCA4 degradation inducers - BioWorld Online
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Sees Significant Decline in Short Interest - MarketBeat
Aprea Therapeutics to Showcase Oncology Advances at Barcelona Symposium - MyChesCo
Prelude Therapeutics Showcases Innovative SMARCA Degrader Programs at Barcelona Symposium - MyChesCo
Prelude Therapeutics shares updates on cancer drug trials By Investing.com - Investing.com Canada
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium - Yahoo Finance
Wall Street today: US stocks trade higher as investors re-evaluate big Fed rate cut potential, Intel Corp. gains 1.83% - MSN
Short Interest in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Increases By 37.0% - MarketBeat
Invesco S&P SmallCap Materials ETF (NASDAQ:PSCM) Short Interest Up 22.6% in September - Defense World
RF Acquisition Corp. (NASDAQ:RFAC) Short Interest Update - Defense World
Squarepoint Ops LLC Grows Stock Holdings in Teleflex Incorporated (NYSE:TFX) - Defense World
Axa S.A. Acquires 1,964 Shares of West Pharmaceutical Services, Inc. (NYSE:WST) - Defense World
Employees Retirement System of Texas Makes New Investment in Nova Ltd. (NASDAQ:NVMI) - Defense World
FDA Issues Draft Guidance on Multiregional Clinical Trials in Oncology - MyChesCo
Firstsource Acquires Ascensos - MENAFN.COM
Firstsource acquires UK-based Ascensos for $56 million - The Economic Times
Angel Capital weaves passage to glory in Guineas Prelude - Horse Betting
Larimar Therapeutics to Present Groundbreaking Nomlabofusp Studies at ICAR Conference - MyChesCo
19 Sundance Movies to Watch Before Seeing These Filmmakers’ New Fall 2024 Releases - Sundance Institute
First Taste: At Prelude, Southern-inspired flavors get the fine-dining spotlight. - 7x7
Prelude Therapeutics (NASDAQ:PRLD) Upgraded to Strong-Buy by HC Wainwright - MarketBeat
Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis - MyChesCo
Data clang on Street for Prelude but SMARCA2 overtures continue - BioWorld Online
Healthy Upside Potential: Prelude Therapeutics Inc (PRLD) - SETE News
Prelude Therapeutics Inc (PRLD) deserves closer scrutiny - US Post News
Prelude Therapeutics (NASDAQ:PRLD) Receives “Market Outperform” Rating from JMP Securities - Defense World
A Closer Look at Prelude Therapeutics Inc (PRLD) Stock Gains - The InvestChronicle
Glioblastoma Treatment Drugs, Pipeline Insights, Emerging Therapies, and Companies 2024 - openPR
We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate - Simply Wall St
Finanzdaten der Prelude Therapeutics Inc-Aktie (PRLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):